Spero Therapeutics, Inc. (SPRO) company profile
Close on Nov 13, 2026Market cap $58.23MP/E –Yield –
About Spero Therapeutics
Pharmaceutical Preparations, SIC 2834
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing treatments for rare diseases and conditions with high unmet medical need. The company's lead clinical-stage product candidate is tebipenem HBr, an oral carbapenem intended for the treatment of complicated urinary tract infections, including pyelonephritis, caused by certain microorganisms in adult patients with limited oral treatment options. Spero previously developed SPR206 for bacterial pneumonia and SPR720 for nontuberculous mycobacterial pulmonary disease, but ceased development of both programs to concentrate resources on advancing tebipenem HBr in collaboration with partner GlaxoSmithKline.
The company operates in the United States and has licensed global rights for the development, manufacture, and commercialization of tebipenem HBr to GlaxoSmithKline. Spero Therapeutics maintains its principal executive offices in Cambridge, Massachusetts.
Summary of the business section of Spero Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Spero Therapeutics, Inc.
- Founded
- 2013
- Headquarters
- Cambridge, MA
- Address
- 675 Massachusetts Avenue, 14th Floor 02139
- Phone
- (857) 242-1600
- Website
- www.sperotherapeutics.com
- Employees
- 25, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- SPRO
- Exchange
- Nasdaq
- IPO date
- Nov 2, 2017
- Shares outstanding
- 58M, Aug 7, 2026
- Public float
- $160.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1701108
- CUSIP
- 84833T103
- ISIN
- US84833T1034
- FIGI
- BBG00HXSJ1R2
- Share class FIGI
- BBG00HXSJ1S1
- LEI
- 54930074G13LHWJT2323
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Esther Rajavelu | See Remarks, Director | 946,000 |
| Debra Zack | Chief Medical Officer | 162,311 |
| Timothy Keutzer | Chief Operating Officer | 742,506 |
| Sath Shukla | CEO & President | 1,886,077 |
| William Ho | Director | – |
| Cynthia Smith | Director | 85,000 |
| John C. Pottage Jr | Director | 85,000 |
| Milind Deshpande | Director | 101,454 |
| Frank E. Thomas | Director | 85,000 |
| Scott Thomas Jackson | Director | 85,000 |
| Patrick V.J.J. Vink | Director | 85,000 |
| Kathleen Tregoning | Director | 85,000 |
| Ankit Mahadevia | Director | 769,111 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr.Mahadevia | $0 | $0 | $1.44M | $12 | – |
| FY2025 Mr.Shukla | $2.03M | $982.03K | $1.44M | $12 | – |
| FY2025 Msrajavelu | $2.06M | $3.34M | $1.44M | $12 | – |
| FY2024 Dr.Mahadevia | $0 | $0 | $944.97K | $5 | – |
| FY2024 Mr.Shukla | $1.95M | $2.25M | $944.97K | $5 | – |
| FY2024 Msrajavelu | $0 | – | $944.97K | $5 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Esther Rajavelu President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer(5) | $577.18K | $687.48K | $413.71K | $372.00K | $11.13K | $2.06M | +141% |
| Tim Keutzer Chief Operating Officer | $484.57K | $498.82K | $213.71K | $232.59K | $11.13K | $1.44M | +39% |
| Satyavrat Shukla Former President and Chief Executive Officer(6) | $244.15K | $452.81K | $603.38K | $307.91K | $416.92K | $2.03M | +4% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 2, 2017
- Offer price
- $14.00
- Securities offered
- 5,500,000
- Gross proceeds
- $77.00M
- Exchange
- Nasdaq
- First trading day
- Nov 2, 2017
- First-day close
- $11.50-17.9%
- Lock-up ends (est.)
- May 1, 2018
“The initial public offering price is $14.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 25 employees, including a total of 6 employees with M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 28, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 2, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 30, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 21, 2017 | Name change | Name changed from Spero Therapeutics, LLC to Spero Therapeutics, Inc. |
See a number that looks wrong?